Circle Wealth Management LLC Has $807,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Circle Wealth Management LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 10.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 3,348 shares of the medical instruments supplier’s stock after selling 372 shares during the quarter. Circle Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $807,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares during the period. Cetera Investment Advisers raised its position in shares of Becton, Dickinson and Company by 380.8% during the first quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock worth $14,580,000 after acquiring an additional 46,668 shares during the last quarter. M&G Plc raised its position in shares of Becton, Dickinson and Company by 0.9% during the second quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock worth $165,967,000 after acquiring an additional 6,052 shares during the last quarter. Benson Investment Management Company Inc. boosted its holdings in Becton, Dickinson and Company by 13.2% in the third quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock valued at $5,380,000 after acquiring an additional 2,602 shares during the last quarter. Finally, Swedbank AB increased its position in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock valued at $36,367,000 after purchasing an additional 2,729 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $221.90 on Friday. The business has a 50-day simple moving average of $234.16 and a 200 day simple moving average of $234.13. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a market capitalization of $64.14 billion, a price-to-earnings ratio of 37.36, a PEG ratio of 1.65 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company posted $3.42 earnings per share. The company’s quarterly revenue was up 6.9% on a year-over-year basis. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. Evercore ISI lifted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.